Abstract

Metastasis and recurrence are major causes of death in gastric cancer patients. Because there are no obvious clinical symptoms during the early stages of metastasis, we sought to isolate highly invasive metastatic gastric cancer cells for future drug screening. We first established a mouse model to observe gastric cancer metastasis in vivo. The incidence of peritoneal metastasis of gastric cancer was much higher than liver or lymph metastasis. Peritoneal metastatic and non-metastatic NUGC-4 cells were isolated from the mouse model. Cell proliferation was measured using CCK-8 assays, while migration and invasion were investigated in Transwell assays. Proteins involved in epithelial-mesenchymal transition were detected by Western blotting. Metastatic gastric carcinoma cells were more proliferative and invasive than primary NUGC-4 cells. The supernatants of metastatic gastric carcinoma cells notably altered the morphology of HMrSV5 peritoneal mesothelial cells and promoted their epithelial-mesenchymal transition. Moreover, primary or metastatic gastric cancer cells co-cultured with HMrSV5 cells markedly increased cancer cell proliferation and invasiveness. Moreover, peritoneal metastatic gastric carcinoma cells in the presence of HMrSV5 cells exhibited most malignant behaviors. Thus, peritoneal metastatic gastric carcinoma cells exhibited high capacities for proliferation and invasion, and could be used as a new drug screening tool for the treatment of advanced gastric cancer and peritoneal metastatic gastric cancer.

Highlights

  • Gastric cancer is the third-leading cause of cancer death worldwide [1]

  • We found that peritoneal metastatic gastric cancer cells exhibited highly malignant behavior, indicating that they could be used as a new tool for drug screening

  • We demonstrated that peritoneal metastatic gastric cancer cells were more malignant and invasive than primary gastric cancer cells in vitro

Read more

Summary

Introduction

Gastric cancer is the third-leading cause of cancer death worldwide [1]. It is estimated that 961,000 new cases of gastric cancer are diagnosed annually [2]. The exact cause of gastric cancer is unclear, its pathogenesis is the same as those of other malignant tumors [3]. Gastric cancer cases can be divided into early- and advancedstage gastric cancer [4], and the stage of the tumor determines the treatment strategy and effectiveness. Earlystage gastric cancer patients typically undergo radical surgery followed by chemotherapy, and the postoperative five-year survival rate is 90% [5]. Advanced-stage gastric cancers include intermediate and advanced tumors [4]. Despite rapid progress in gastric cancer research, there is still no effective treatment for advanced gastric cancer

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call